Debio1347, an Oral FGFR Inhibitor: Results From a Single-Center Study in Pediatric Patients With Recurrent or Refractory FGFR-Altered Gliomas-Reference-Cited by-同舟云学术

Debio1347, an Oral FGFR Inhibitor: Results From a Single-Center Study in Pediatric Patients With Recurrent or Refractory FGFR-Altered Gliomas

Published:2021-05 Issue:5 Volume: Page:876-883
ISSN:2473-4284
Container-title:JCO Precision Oncology
language:en
Short-container-title:JCO Precision Oncology

Author:

Farouk Sait Sameer¹²^ORCID,Gilheeney Stephen W.¹²,Bale Tejus A.³^ORCID,Haque Sofia⁴^ORCID,Dinkin Marc J.⁵^ORCID,Vitolano Stephanie¹^ORCID,Rosenblum Marc K.³^ORCID,Ibanez Katarzyna⁶^ORCID,Prince Daniel E.⁷^ORCID,Spatz Krisoula H.⁸^ORCID,Dunkel Ira J.¹²^ORCID,Karajannis Matthias A.¹²^ORCID

Affiliation:

1. Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY

2. Department of Pediatrics, Weill Cornell Medical College, New York, NY

3. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY

4. Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY

5. Department of Ophthalmology and Neurology, Weill Cornell Medical College, New York, NY

6. Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY

7. Department of Orthopedics, Memorial Sloan Kettering Cancer Center, New York, NY

8. Department of Pharmacy, Memorial Sloan Kettering Cancer Center, New York, NY

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

https://ascopubs.org/doi/pdfdirect/10.1200/PO.20.00444

Reference22 articles.

1. Fibroblast Growth Factor (FGF) Receptor/FGF Inhibitors: Novel Targets and Strategies for Optimization of Response of Solid Tumors

2. Emergence of FGFR family gene fusions as therapeutic targets in a wide spectrum of solid tumours

3. Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors

4. Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas

5. The Fibroblast Growth Factor Receptor Genetic Status as a Potential Predictor of the Sensitivity to CH5183284/Debio 1347, a Novel Selective FGFR Inhibitor

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular characterization of gliomas and glioneuronal tumors amid Noonan syndrome: cancer predisposition examined;Frontiers in Oncology;2024-09-06

2. A diverse landscape of FGFR alterations and co-mutations defines novel therapeutic strategies in pediatric low-grade gliomas;2024-08-28

3. Prolonged Clinical Benefit with Futibatinib in a Patient with FGFR Inhibitor–Pretreated FGFR2 Fusion–Positive Intrahepatic Cholangiocarcinoma: Case Report;OncoTargets and Therapy;2024-06

4. Case report: Slipped capital femoral epiphysis: a rare adverse event associated with FGFR tyrosine kinase inhibitor therapy in a child;Frontiers in Oncology;2024-05-24

5. Pediatric-type low-grade gliomas in adolescents and young adults—challenges and emerging paradigms;Child's Nervous System;2024-05-18